In Phase A, participants will get various doses and schedules of oral ABBV-744 tablet to detect Risk-free dosing program. Further members will probably be enrolled for the discovered monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Phase C, https://abbv-744-drug-development80357.onesmablog.com/5-tips-about-clinical-effectiveness-of-abbv-744-in-aml-patients-you-can-use-today-72511172